• 医学文献
  • 知识库
  • 评价分析
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
  • 临床诊疗知识库
  • 中医药知识库
  • 机构
  • 作者
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

医学文献>>
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
热搜词:
换一批

Mechanistic engineering of celastrol liposomes induces ferroptosis and apoptosis by directly targeting VDAC2 in hepatocellular carcinoma

摘要Hepatocellular carcinoma(HCC)is one of most common and deadliest malignancies.Celastrol(Cel),a natural product derived from the Tripterygium wilfordii plant,has been extensively researched for its potential effectiveness in fighting cancer.However,its clinical application has been hindered by the unclear mechanism of action.Here,we used chemical proteomics to identify the direct targets of Cel and enhanced its targetability and anti-tumor capacity by developing a Cel-based liposomes in HCC.We demonstrated that Cel selectively targets the voltage-dependent anion channel 2(VDAC2).Cel directly binds to the cysteine residues of VDAC2,and induces cytochrome C release via dysregulating VDAC2-mediated mitochondrial permeability transition pore(mPTP)function.We further found that Cel induces ROS-mediated ferroptosis and apoptosis in HCC cells.Moreover,coencapsulation of Cel into alkyl glucoside-modified liposomes(AGCL)improved its antitumor efficacy and minimized its side effects.AGCL has been shown to effectively suppress the proliferation of tumor cells.In a xenograft nude mice experiment,AGCL significantly inhibited tumor growth and promoted apoptosis.Our findings reveal that Cel directly targets VDAC2 to induce mitochondria-dependent cell death,while the Cel liposomes enhance its targetability and reduces side effects.Overall,Cel shows promise as a therapeutic agent for HCC.

更多
广告
作者 Piao Luo [1] Qian Zhang [1] Shuo Shen [2] Yehai An [1] Lixia Yuan [1] Yin-Kwan Wong [3] Sizhe Huang [1] Shaohui Huang [1] Jingnan Huang [4] Guangqing Cheng [2] Jiahang Tian [1] Yu Chen [1] Xiaoyong Zhang [1] Weiguang Li [5] Songqi He [1] Jigang Wang [6] Qingfeng Du [1] 学术成果认领
作者单位 School of Traditional Chinese Medicine and School of Pharmaceutical Sciences,Southern Medical University,Guangzhou 510515,China [1] State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs,Artemisinin Research Center,and Institute of Chinese Materia Medica,China Academy of Chinese Medical Sciences,Beijing 100700,China [2] Department of Biological Sciences,National University of Singapore,Singapore 117543,Singapore [3] Department of Nephrology,Shenzhen key Laboratory of Kidney Diseases,and Shenzhen Clinical Research Centre for Geriatrics,Shenzhen People's Hospital,The First Affiliated Hospital,Southern University of Science and Technology,Shenzhen 518020,China [4] Department of Health Technology and Informatics,The Hong Kong Polytechnic University,Hong Kong 100872,China [5] School of Traditional Chinese Medicine and School of Pharmaceutical Sciences,Southern Medical University,Guangzhou 510515,China;State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs,Artemisinin Research Center,and Institute of Chinese Materia Medica,China Academy of Chinese Medical Sciences,Beijing 100700,China;Department of Biological Sciences,National University of Singapore,Singapore 117543,Singapore;Department of Oncology,the Affiliated Hospital of Southwest Medical University,Luzhou 646000,China;National Pharmaceutical Engineering Center for Solid Preparation of Chinese Herbal Medicine,Jiangxi University of Chinese Medicine,Nanchang 330006,China [6]
栏目名称 Research articles
DOI 10.1016/j.ajps.2023.100874
发布时间 2024-06-07
提交
  • 浏览2
  • 下载0
亚洲药物制剂科学(英文版)

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷